Sapphiros is at the forefront of advancing healthcare diagnostics through a diverse portfolio of innovative technologies. The company focuses on high-performance computing, machine learning, and artificial intelligence to enhance biochemistry, cell biology, and diagnostics. Their subsidiaries, such as Sapphiros Laboratories, specialize in genetic and COVID-19 testing, while GrapheneDx is developing a device aimed at delivering high-performance diagnostics directly to consumers in a home setting. Additionally, the SatioPatch™ Platform offers a user-friendly solution for rapid, point-of-care diagnosis, and Biocrucible is working on proprietary molecular detection technologies that enable near-patient and at-home testing for infectious diseases.

Sapphiros also emphasizes collaboration and strategic partnerships to expand access to diagnostic insights. Their recent collaboration with OraSure Technologies aims to leverage existing commercial infrastructure to scale their innovations efficiently post-regulatory approval. The company is committed to bridging the gap between current and future diagnostic capabilities, empowering entrepreneurs and supporting the development of transformative technologies that can significantly impact global health. Through these initiatives, Sapphiros is dedicated to delivering extraordinary and disruptive innovations that enhance healthcare outcomes.

United States

Sapphiros, backed by Neoenta and KKR, is a privately held consumer diagnostic portfolio company. The Sapphiros portfolio includes novel sample collection, next generation diagnostics, computational biology, and printed electronics to help consumers access important diagnostic results globally. Knowing Now Moves Us™

Knowledge empowers us to navigate through life's choices and decisions. With solutions that provide real-time, definitive results; at Sapphiros we work together to help global communities act on these insights with confidence.

Sapphiros

Company Details